Novogene Past Earnings Performance
Past criteria checks 3/6
Novogene has been growing earnings at an average annual rate of 21.9%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 10.1% per year. Novogene's return on equity is 7.7%, and it has net margins of 9%.
Key information
21.9%
Earnings growth rate
19.1%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 10.1% |
| Return on equity | 7.7% |
| Net Margin | 9.0% |
| Next Earnings Update | 15 Aug 2024 |
Revenue & Expenses Breakdown
How Novogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,030 | 183 | 587 | 123 |
| 31 Dec 23 | 2,002 | 178 | 572 | 124 |
| 30 Sep 23 | 1,990 | 190 | 546 | 129 |
| 30 Jun 23 | 2,006 | 196 | 550 | 126 |
| 31 Mar 23 | 1,980 | 181 | 541 | 126 |
| 31 Dec 22 | 1,926 | 177 | 531 | 126 |
| 30 Sep 22 | 1,955 | 209 | 530 | 138 |
| 30 Jun 22 | 1,914 | 200 | 505 | 143 |
| 31 Mar 22 | 1,888 | 211 | 465 | 139 |
| 31 Dec 21 | 1,866 | 225 | 444 | 145 |
| 30 Sep 21 | 1,812 | 218 | 415 | 129 |
| 30 Jun 21 | 1,707 | 193 | 382 | 113 |
| 31 Mar 21 | 1,633 | 132 | 380 | 115 |
| 31 Dec 20 | 1,490 | 37 | 369 | 112 |
| 30 Sep 20 | 1,437 | -10 | 374 | 125 |
| 30 Jun 20 | 1,550 | 9 | 397 | 143 |
| 31 Mar 20 | 1,472 | 37 | 380 | 134 |
| 31 Dec 19 | 1,535 | 114 | 366 | 126 |
| 30 Sep 19 | 1,377 | 107 | 342 | 105 |
| 30 Jun 19 | 1,219 | 100 | 318 | 85 |
| 31 Mar 19 | 1,137 | 99 | 295 | 82 |
| 31 Dec 18 | 1,054 | 97 | 272 | 79 |
| 31 Dec 17 | 739 | 81 | 209 | 50 |
| 31 Dec 16 | 458 | 39 | 144 | 31 |
| 31 Dec 15 | 310 | 25 | 86 | 45 |
Quality Earnings: 688315 has high quality earnings.
Growing Profit Margin: 688315's current net profit margins (9%) are lower than last year (9.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688315's earnings have grown significantly by 21.9% per year over the past 5 years.
Accelerating Growth: 688315's earnings growth over the past year (1.1%) is below its 5-year average (21.9% per year).
Earnings vs Industry: 688315 earnings growth over the past year (1.1%) exceeded the Life Sciences industry 0.7%.
Return on Equity
High ROE: 688315's Return on Equity (7.7%) is considered low.